Is ICU Medical (ICUI) Undervalued As Russell Index Removal Triggers Rebalancing?
ICU Medical (ICUI) was recently removed from several Russell growth benchmarks, triggering portfolio rebalancing by index-tracking investors. Despite this, its stock has shown short-term momentum with recent gains. The company is considered undervalued by some analyses, with a fair value target significantly above its current trading price, although its P/E ratio appears high compared to peers, suggesting future profit improvements are already factored in.
ICU Medical Inc business profile and stock context
ICU Medical Inc is a global medical technology company listed on Nasdaq, specializing in the design, manufacture, and sale of infusion systems and medical devices used in hospitals and clinical settings. The company focuses on improving the safety and efficiency of intravenous therapies, offering products from IV sets to integrated hardware and software solutions. Its stock performance is influenced by hospital spending, procedure volumes, and the evolving landscape of healthcare technology, with an emphasis on recurring sales of consumables.
Does ICU Medical’s (ICUI) Russell Growth Exit Hint at a Shifting Long-Term Portfolio Role?
ICU Medical (ICUI) was removed from several Russell growth indices in late June 2026, which may impact its short-term trading and investment narrative. The company's investment case relies on steady demand for its medical devices and improved profitability, despite ongoing integration, restructuring, and quality-related costs, including a recent oncology kit recall. Despite these challenges, ICU Medical's narrative projects significant revenue and earnings growth, leading to a fair value estimate of $172.50.
Price to sales forward of ICU Medical, Inc. – NASDAQ:ICUI
This article displays the forward price-to-sales ratio for ICU Medical, Inc. (NASDAQ: ICUI). It presents the current value and its change over a period, accessible through TradingView. The content primarily focuses on financial data for the company.
Price to earnings forward of ICU Medical, Inc. – NASDAQ:ICUI
This article provides the forward price-to-earnings ratio for ICU Medical, Inc. (NASDAQ: ICUI). It is presented as part of a financial overview on TradingView, indicating the company's valuation based on future earnings estimates. The content itself is very brief, showing "Period Value Change Change % Made by humans" under the main heading.
Price to earnings forward of ICU Medical, Inc. – DUS:IC7
This article provides financial data for ICU Medical, Inc. under the stock symbol IC7 on the Dusseldorf Stock Exchange. It specifically highlights the "Price to earnings forward" metric. The page is part of a larger financial data platform by TradingView.
Enterprise value to EBITDA forward of ICU Medical, Inc. – NASDAQ:ICUI
This article provides the enterprise value to EBITDA forward for ICU Medical, Inc. (NASDAQ: ICUI). It appears to be a financial data point from TradingView, indicating a specific valuation metric for the company. The page focuses on the financial data rather than providing a detailed analysis.
Understanding the Setup: (ICUI) and Scalable Risk
Icu Medical Inc. (NASDAQ: ICUI) is exhibiting a mid-channel oscillation pattern with strong near and mid-term sentiment that could extend long-term. An exceptional 35.6:1 risk-reward short setup targets a 10.4% downside with only 0.3% risk. AI models have generated distinct trading strategies including a Position Trading Strategy, a Momentum Breakout Strategy, and a Risk Hedging Strategy.
ICUI Forecast — Price Target — Prediction for 2027
This article provides a forecast and price target for ICU Medical, Inc. (ICUI), detailing analyst opinions, historical stock performance, and key financial metrics. It highlights the current stock price, volatility, market capitalization, and upcoming earnings report, along with revenue and net income figures. The article also touches on the company's dividend policy and employee count.
ICU Medical (ICUI) Stock Forum and Discussion
This document appears to be a stub or an empty placeholder for a stock forum and discussion about ICU Medical (ICUI). There is no actual content provided beyond the title. The purpose is likely to host future discussions or information related to ICUI stock.
Moody’s upgrades ICU Medical rating to Ba3 on leverage outlook By Investing.com
Moody's Ratings has upgraded ICU Medical, Inc. (NASDAQ:ICUI) to Ba3 from B1, anticipating a decline in the company's financial leverage over the next 12 months. This upgrade is based on expectations of adjusted debt to EBITDA remaining below 4.0x, driven by revenue growth, strong free cash flow, and debt reduction efforts. The rating is supported by ICU Medical's market position and recurring revenue but is constrained by modest scale and regulatory risks in its infusion pump business.
Moody’s upgrades ICU Medical rating to Ba3 on leverage outlook
Moody's Ratings has upgraded ICU Medical, Inc. (NASDAQ:ICUI) to Ba3 from B1, anticipating that the company's financial leverage will decrease over the next 12 months. This upgrade is driven by expected low single-digit revenue growth, strong free cash flow generation, and continued debt reduction, which should keep adjusted debt to EBITDA below 4.0x. The company's stable outlook is supported by its strong position in the IV infusion therapy market and ongoing cost improvement initiatives.
ICU Medical Inc (ICUI) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of ICU Medical Inc (ICUI), listing major institutional holders like BlackRock, Janus Henderson Investors, and Wasatch Global Investors. It also provides a breakdown of shareholder types and historical institutional shareholding data from 2023Q4 to 2026Q1. Additionally, the report identifies related ETFs that hold ICUI stock.
Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks Q1 Earnings: ICU Medical (NASDAQ:ICUI) Firing on All Cylinders
The article reviews Q1 earnings for several medical device companies in the cardiology, neurology, and vascular sectors. ICU Medical (ICUI) reported strong Q1 results, beating analyst estimates, while Merit Medical Systems (MMSI) also had a good quarter. Artivion (AORT) and Penumbra (PEN) experienced weaker performance, with Artivion significantly missing EPS estimates.
Medical device manufacturer proposes 2.4M SF facility in NW Austin
ICU Medical Inc. is planning a substantial 2.4-million-square-foot industrial park in Northwest Austin. This development is set to replace existing pastures with large buildings, marking one of the biggest projects in North Austin. The medical technology company's plans highlight the significant growth in Austin's health care and life sciences sector.
Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks Q1 Earnings: ICU Medical (NASDAQ:ICUI) Firing on All Cylinders
ICU Medical (NASDAQ:ICUI) led medical devices and supplies companies in Q1 earnings, exceeding analyst expectations despite a revenue decline. Other companies like Merit Medical Systems (NASDAQ:MMSI) also beat revenue expectations, while Artivion (NYSE:AORT) and Penumbra (NYSE:PEN) faced weaker quarters with EPS misses. The sector as a whole experienced a mixed Q1, with revenues slightly beating estimates but share prices declining by an average of 6.9% since earnings reports.
BTIG Initiates ICU Medical(ICUI.US) With Buy Rating, Announces Target Price $170
BTIG has initiated coverage of ICU Medical (ICUI.US) with a Buy rating. The firm has set a price target of $170 for the company's stock. This indicates a positive outlook from BTIG regarding ICU Medical's future performance.
BTIG initiates ICU Medical stock coverage with buy rating
BTIG has initiated coverage on ICU Medical Inc. (NASDAQ:ICUI) with a Buy rating and a price target of $170.00, citing the company's pure-play infusion therapy business and potential for market share gains from competitors. The firm anticipates ICU Medical's free cash flow to improve as integration costs wind down and expects gross margins to reach 43% by late 2027. Recent developments include strong Q1 2026 earnings, a Needham upgrade, and shareholder approval of charter amendments simplifying voting requirements.
This ICU Medical Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
This article highlights top analyst initiations for Monday, focusing on ICU Medical Inc. BTIG analyst Sam Eiber initiated coverage on ICU Medical with a Buy rating and a $170 price target. The piece also details new Buy ratings for Biodesix Inc by HC Wainwright & Co. and Ceva Inc by Needham, along with ratings for Lincoln International Inc and ESCO Technologies Inc.
ICUI Initiated by BTIG -- Price Target Announced at $170
BTIG has initiated coverage on ICU Medical (ICUI) with a 'Buy' rating and a price target of $170, indicating a positive outlook for the company's future performance. Despite this, GuruFocus assesses ICUI as 18.2% overvalued with a GF Value of $120.35 against a current price of $142.27. However, the company holds a strong GF Score of 81/100, driven by robust profitability and growth, while insider selling of $0.9 million over the last three months warrants investor consideration.
BTIG initiates ICU Medical stock coverage with buy rating
BTIG has initiated coverage on ICU Medical Inc. (ICUI) with a Buy rating and a price target of $170, citing the company's strong position as a pure-play infusion therapy provider and opportunities arising from competitive disruption in the U.S. large volume pump market. The firm anticipates significant free cash flow and gross margin improvements as integration costs wind down and expects a unified software platform to strengthen its market presence. ICU Medical recently surpassed Q1 2026 earnings and revenue expectations, and also approved changes to its charter to simplify voting requirements and allow stockholders to call special meetings.
Are Insider Sales and Fund Buying Sending Mixed Signals About ICU Medical’s Competitive Edge (ICUI)?
In May 2026, ICU Medical's General Counsel sold shares while the Smiths Medical integration was completing, and concurrently, Madison Small Cap Fund acquired a new position, driven by the company's focus on infusion therapy and a high-volume connected pump. This creates mixed signals for investors, as the fund's investment highlights the potential of the connected pump which shareholders see as a key upside driver. The article details the investment narrative, emphasizing ICU Medical's projected revenue and earnings, and discusses the company's fair value.
ICUI Financials: Revenue Breakdown, Margins & Competitor Comparison
The article provides a detailed financial analysis of ICU Medical Inc (ICUI), focusing on its revenue breakdown, profitability margins, and a comparison with competitors. ICUI generates significant revenue from Consumables, and its gross margin is 38.89%. The company, with a market capitalization of $3.55B, is benchmarked against NNNN and IRTC to evaluate its financial performance within the Medical Equipment, Supplies & Distribution industry.
ICU Medical (ICUI) Strengthens Amid Competitors’ Quality Issues
ICU Medical, Inc. (ICUI), a medical device company specializing in infusion therapy, has been highlighted by Madison Small Cap Fund as a new position. The company is gaining market share due to quality issues faced by competitors Becton Dickinson (BDX) and Baxter (BAX), and its new high-volume pump with connected features is expected to drive retention and incremental revenue. Despite a recent market underperformance, the fund views ICUI as well-positioned in a volatile market with a valuation of 12x EBITDA, estimating its intrinsic value at approximately $200/share.
ICU Medical (ICUI) Valuation Check After Recent Short Term Share Price Momentum
ICU Medical (ICUI) has seen recent short-term share price momentum, closing at $139.83, despite a longer-term decline. Analysts consider the stock undervalued with a fair value estimate of $172.86, driven by an anticipated multiyear replacement cycle for its infusion pumps. However, the current P/E ratio of 75.4x is significantly higher than the industry average, raising concerns about valuation risk if market sentiment shifts.
ICU Medical (ICUI) Valuation Check After Recent Short Term Share Price Momentum
ICU Medical (ICUI) has seen a recent surge in short-term share price momentum, though its 3-year return is down. The company is considered 19.1% undervalued with a fair value of $172.86 according to analyst narratives, driven by expectations of revenue growth from infusion pump replacement cycles. However, its current P/E ratio of 75.4x is significantly higher than industry averages, raising valuation risk concerns.
ICU Medical's General Counsel Sells — The Smiths Integration Is Almost Done, the Proof Isn'tICU Medical's General Counsel Sells — The Smiths Integration Is still playing out.
ICU Medical's General Counsel, Virginia Ruth Sanzone, sold 2,447 shares of company stock for approximately $304,000. This sale represents Sanzone's largest direct sale in the last year, reducing her holdings by over 11%. The article questions whether ICU Medical is a worthwhile investment, emphasizing the ongoing challenges of the Smiths Medical integration and significant debt against a backdrop of rising interest rates and tariff headwinds.
ICU Medical's General Counsel Sells — The Smiths Integration Is Almost Done, the Proof Isn't
ICU Medical's General Counsel, Virginia Ruth Sanzone, sold 2,447 shares of common stock for approximately $304,000, representing 11.17% of her direct holdings. This sale is the largest direct sale Sanzone has made in the past year, occurring as the company continues to integrate the 2022 Smiths Medical acquisition and faces challenges with debt and tariffs. While the integration is nearing completion with expected margin improvements, the company's past struggles to meet promises and current economic headwinds make it a "show-me" story for investors.
ICU Medical Inc stock (US44930G1076): earnings, integration progress and what matters for investors
ICU Medical Inc recently reported its latest quarterly figures and is continuing the integration of its Smiths Medical acquisition, while managing a mixed demand and margin environment. The article details the company's core business model, key revenue and product drivers, and what its numbers and guidance mean for investors. It notes ICU Medical's focus on infusion therapy, oncology, and critical care products, highlighting its recurring revenue model from disposable components and its strategic contracts with healthcare organizations.
Norges Bank Makes New $58.08 Million Investment in ICU Medical, Inc. $ICUI
Norges Bank has made a new $58.08 million investment in ICU Medical, acquiring 407,115 shares and now owning approximately 1.65% of the company. This comes as ICU Medical reported quarterly earnings that beat expectations, with EPS of $1.97, despite a 12.3% year-over-year revenue decrease. The stock currently holds a "Buy" consensus rating from analysts, with an average price target of $168.
Precision Trading with Icu Medical Inc. (ICUI) Risk Zones
This article provides a detailed analysis of Icu Medical Inc. (ICUI) focusing on risk zones and trading strategies based on AI models. It highlights conflicting sentiment across different time horizons, suggesting choppy conditions, and offers specific position trading, momentum breakout, and risk hedging strategies with entry points, targets, and stop losses. The analysis also includes multi-timeframe signal strength, support, and resistance levels for the stock.
ICUI PE Ratio & Valuation, Is ICUI Overvalued
ICU Medical Inc. (ICUI) is currently considered undervalued, with its fair price estimated to be between $168.98 and $254.95, compared to its current price of $130.52. Despite this, its P/S ratio of 1.43 is significantly above the industry average, which, coupled with a -12.32% revenue growth, suggests this premium may be unsustainable. The article provides detailed valuation metrics such as P/B ratio, FCF yield, and forward P/E and P/S ratios to support this assessment.
ICU Medical’s New Voting Rules Could Be A Game Changer For ICU Medical (ICUI)
ICU Medical shareholders recently approved significant governance changes, including the removal of supermajority voting thresholds and the ability for investors holding at least 25% of voting power to call special meetings. These changes aim to increase shareholder influence and reflect an incremental cleanup of the company's governance structure. While these shifts don't immediately impact earnings, they reshape how quickly shareholders can react if operational efforts fall short of expectations, against a backdrop of the company recently returning to profitability and projecting future revenue and earnings growth.
ICU Medical’s New Voting Rules Could Be A Game Changer For ICU Medical (ICUI)
ICU Medical shareholders recently approved amendments to the company's charter and bylaws, removing supermajority voting thresholds and granting investors holding at least 25% of voting power the ability to call special meetings. This shift, while seen as an incremental governance improvement, suggests rising shareholder influence. The changes primarily impact how quickly shareholders can react if the company's integration, restructuring, or new product launches do not meet expectations, rather than immediately affecting near-term earnings.
A Look At ICU Medical (ICUI) Valuation After Governance Changes Expand Shareholder Meeting Rights
ICU Medical (ICUI) has implemented significant governance changes, lowering the threshold for shareholder-initiated special meetings and ordinary resolutions. Despite a recent boost in share price, the company's 3-year and 5-year total shareholder returns are down. The article explores whether the stock, currently trading below its estimated fair value of $180.17, presents a genuine investment opportunity or if its high P/E ratio signals valuation risks.
ICU Medical Shares Rise After Needham Upgrade
ICU Medical shares saw a significant rise following an upgrade from "Hold" to "Buy" by Needham. The analyst, Mike Matson, cited an improved outlook for the company's infusion systems business, particularly with the recent resolution of product availability issues. Needham also raised its price target for ICU Medical to $145.
Icu Medical Inc Faces Fda Enforcement Action for Oncology Kit Leak Risk
ICU Medical Inc. is facing an enforcement report from the FDA regarding a Class II recall of its Oncology Kit with extension sets. The recall, initiated voluntarily by the firm on March 24, 2026, is due to a leak risk that could lead to therapy delays, interruption, or exposure to hazardous substances for patients and caregivers. Approximately 20,506 units are affected nationwide across the US.
Needham Upgrades ICU Medical(ICUI.US) to Buy Rating, Announces Target Price $165
Needham has upgraded ICU Medical (ICUI.US) to a Buy rating from a Hold rating, setting a new price target of $165. This upgrade reflects a positive outlook on the company's stock performance.
Needham upgrades ICU Medical stock rating to buy on replacement cycle
Needham has upgraded ICU Medical (NASDAQ:ICUI) shares from hold to buy, setting a price target of $165.00, citing an anticipated IV system replacement cycle and competitors' challenges. The firm believes ICU Medical is attractively valued at 16.5 times its 2026 EPS estimate, in line with GARP peers and below medical supplies peers, and expects strong margin improvement and future share repurchases. ICU Medical recently surpassed Q1 2026 earnings and revenue expectations and shareholders approved corporate governance amendments.
Technical Reactions to ICUI Trends in Macro Strategies
The article provides a technical analysis of Icu Medical Inc. (NASDAQ: ICUI), highlighting strong near and mid-term sentiment that could extend long-term. It details three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis also includes multi-timeframe signal analysis with support and resistance levels.
Insider Sell: Daniel Woolson Sells Shares of ICU Medical Inc (ICUI)
Daniel Woolson, President of a branch of ICU Medical Inc (ICUI), recently sold 2,123 shares of the company, reducing his total holdings to 22,479 shares. This sale is part of a larger trend for Woolson, who has sold 5,020 shares over the past year without any purchases. ICU Medical Inc's stock is currently considered modestly overvalued with a price-to-GF-Value ratio of 1.1, and its price-earnings ratio of 72.06 is significantly higher than the industry median.
Insider Sell: Daniel Woolson Sells Shares of ICU Medical Inc (ICUI)
Daniel Woolson, President of a branch of ICU Medical Inc (ICUI), sold 2,123 shares of the company on May 22, 2026. This transaction brings his total holdings to 22,479 shares. The stock is currently trading at $132.21, with a price-earnings ratio of 72.06 and a price-to-GF-Value ratio of 1.1, indicating it is modestly overvalued based on GuruFocus's intrinsic value estimate.
ICU Medical president Daniel Woolson disposes of $280,684 in stock.
Daniel Woolson, President of ICU Medical Inc. (NASDAQ:ICUI), sold 2,123 shares of company stock on May 22, 2026, for a total of approximately $280,684 at an average price of $132.2114 per share. Following this transaction, Woolson retains 22,479 shares. The article also notes that ICU Medical recently surpassed Q1 2026 earnings expectations and approved charter amendments to eliminate supermajority voting requirements and allow shareholders with 25% voting power to call special meetings.
A Look At ICU Medical (ICUI) Valuation After Strong Q1 2026 Earnings Beat
ICU Medical (ICUI) recently beat Q1 2026 earnings expectations, causing a short-term rise in its share price despite long-term declines. The stock is trading at a significant discount to its estimated intrinsic value and analyst price targets, with a prevailing narrative suggesting it is 28.2% undervalued. However, its high P/E ratio compared to the industry indicates that the market might be overpaying for its recovery prospects.
[144] ICU MEDICAL INC/DE SEC Filing
This SEC Form 144 filing from ICU Medical Inc. (ICUI) reports proposed sales of common-equity awards, primarily Performance Stock Units and restricted stock. The filing details the planned disposal of 2,123 units with an aggregate market value of $280,684.80, scheduled for May 22, 2026, through Morgan Stanley Smith Barney LLC. The document explicitly states that the filer doesn't know of any material adverse information not publicly disclosed.
[Form 4] ICU MEDICAL INC/DE Insider Trading Activity
ICU Medical Inc.'s President, Daniel Woolson, reported an open-market sale of 2,123 shares of common stock at a weighted average price of $132.2114 per share, totaling approximately $280,685. Following this transaction, Woolson directly holds 22,479 shares. The Form 4 filing indicates the sale occurred on May 22, 2026, with trade prices ranging from $132.03 to $132.33.
A Look At ICU Medical (ICUI) Valuation After Strong Q1 2026 Earnings Beat
ICU Medical (ICUI) beat Wall Street expectations for Q1 2026 earnings, leading to a short-term share price bounce. Despite a 26% discount to its estimated intrinsic value and 35% below analyst targets, the stock's valuation is complex due to a high P/E ratio compared to industry averages and potential risks from tariffs and regulatory scrutiny. The article suggests investors should conduct further analysis to weigh the risks and rewards.
ICU Medical's Valuation Upgrade Signals Strong Financial Health and Market Potential
ICU Medical, Inc. has received a significant valuation upgrade, moving from "fair" to "very attractive," based on its strong financial metrics. Key indicators such as a P/E ratio of 47, an EV to EBITDA ratio of 13.11, and a low PEG ratio of 0.23 suggest a solid operational efficiency and potential undervaluation relative to growth. The company also demonstrates strong fundamentals with a robust EBIT to interest ratio of 16.14 and reported a net profit of USD 14.46 million for the quarter ending December 2025.
Is ICU Medical’s Profit Rebound Despite Lower Sales Altering The Investment Case For ICU Medical (ICUI)?
ICU Medical, Inc. reported a return to profitability in Q1 2026, with net income of US$30.13 million despite lower sales, indicating improved cost control. While this supports a near-term margin improvement catalyst, potential risks from tariffs and restructuring costs remain. The company's future projections include $2.4 billion revenue and $138.5 million earnings by 2029, suggesting a fair value of $180.17 per share.
ICU Medical shareholders approve charter amendments and director elections
ICU Medical shareholders approved several amendments to the company's charter at their 2026 annual meeting, including eliminating supermajority voting requirements and allowing stockholders holding at least 25% of voting power to call special meetings. They also elected directors and ratified Deloitte & Touche LLP as their independent registered public accounting firm. The company's Q1 2026 earnings surpassed analyst expectations.
